Aqilion strengthens its pipeline with a drug candidate in chronic inflammatory bowel diseases, IBD
Aqilion has nominated Girtab, a program from the company’s research activities, for further preclinical and clinical development. The goal of Girtab is to develop a new treatment for chronic inflammatory bowel diseases. Girtab complements Aqilion’s pipeline well and strengthens the company’s strategic focus on drug targets and programs with great potential in inflammatory diseases. The development of Girtab has come so far that there is now a clinical drug candidate, AQ312, to be tested in safety studies in a preclinical development program. In parallel, the development of a dosage form
